Rethinking Consent in NHS Data: From Access to Agency

The paradox is familiar. We ask the public to trust digital health, yet we present opaque systems, unclear choices, and paperwork that fails to reflect real life. People want better care and better research. They also want control. In the UK, opt outs exist, pilots progress, and platforms scale. Still, confidence remains fragile. Trust is not a banner. It is a system design choice.

Policy has moved. The NHS and the Department of Health and Social Care have set direction on secure data access and public benefit. The Information Commissioner’s Office has clarified principles for lawful processing, transparency, and accountability under UK GDPR. These are necessary foundations. They are not yet sufficient. Consent in practice is often episodic and static. Data use is continuous and dynamic. That gap erodes confidence.

There is a better framing. Shift from access to agency. Consent is not a single tick box. It is a living agreement between a person and the system. It requires clarity, auditability, and the right to change one’s mind. It should travel with the data across settings. It should be easy to understand, easy to revoke, and easy to verify.

Blockchain offers useful primitives for this. Immutability for audit trails. Distributed consensus for integrity. Cryptographic proofs for verifiable events. When combined with strong privacy controls, role based access, and data minimisation, these tools can make consent legible and enforceable. Patient data ownership sits at the heart of this model. Ownership is not a slogan. It is a set of rights, controls, and verifiable records.

At BlockMed Pro we call this the One True Record. It is a patient anchored ledger of permissions and provenance across systems. It is designed to interoperate with clinical standards and existing infrastructure. It does not hold raw clinical detail on chain. It records consent events, policy states, and data lineage. That is how we align with GDPR by design. Learn more about the One True Record by visiting our website.

Consider a practical NHS use case. An Integrated Care System wants to support population health analytics with strict governance. Each patient has a clear consent profile. Analysts request an approved query. The system checks purpose, role, and scope against the consent ledger. It logs access outcomes. It produces an audit trail that the patient, the ICS, and the regulator can verify. If a patient updates preferences, the future access path respects that change. This is consent as a continuous control.

Now consider research and pharma. A sponsor seeks a consented cohort for a safety signal study. Today this often involves slow recruitment and blanket forms. With a patient owned model, individuals discover opportunities through a transparent marketplace that describes purpose, benefit, and safeguards. People opt in with granular terms, for defined durations, with revocation options. The sponsor gains data that is lawful, ethical, and provenance rich. The public gains agency and clarity. Explore our Marketplace.

Interoperability matters. Consent that cannot cross system boundaries is theatre. We integrate with existing data flows and standards so that permissions and provenance are portable. That is how we move from local policy statements to practical accountability. It also supports external oversight. An auditable map of who accessed what, when, and why reduces ambiguity. It invites independent scrutiny. It builds trust by making governance visible.

There are constraints. Not every policy question is solved by technology. Public engagement is essential. Clear language is essential. Independent assurance is essential. The ICO’s expectations on transparency and fairness remain baseline. UK GDPR still governs the lawful basis for each purpose. Clinical safety and cyber security obligations still apply. Our role is to make the right thing the easy thing. We do that by encoding policy as enforceable controls.

The principle is simple. Consent should be continuous, comprehensible, and controllable. Equity should be designed in. Those with less digital access should not be left behind. Incentives should align with public benefit. If we can make policy legible to patients and provable to regulators, trust will follow. That is the future we are building toward.

If you want to understand the people and purpose behind this work, visit BlockMed Pro.